Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study

Association HGE CHU Bordeaux Sud277 enrolled

Overview

The aim of this study is to evaluate liver fibrosis using FibroScan and biochemical markers in patients with diabetes.

Patients with diabetes are at risk for nonalcoholic fatty liver disease (NAFLD) leading to advanced fibrosis, cirrhosis, and liver cancer. However, liver fibrosis screening in this large population needs non-invasive methods. Recently, FibroScan was shown to be a good method for the diagnosis of advanced fibrosis in NAFLD patients. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) and transient elastography (FibroScan) in patients with diabetes.

Study Type

OBSERVATIONAL

Enrollment

277

Conditions

Diabetes

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female subjects * More than 18 years of age * Patients with Diabetes * Written informed consent Exclusion Criteria: * Patients refusing to participate to the study and to provide written informed consent

Locations (1)

Service Hepato-Gastroentérologie Hopital Haut-Leveque

Pessac, France

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.